ADCC Screening Services

Antibody-dependent cell-mediated cytotoxicity, or ADCC, is an immune reaction used to lyse specific target cells. Antibodies bind to antigens on target cell surfaces and these antibodies are recognized by effector cells. When the effector cell binds to these antibodies through Fc receptors, it triggers the target cell to undergo apoptosis. Immune cells such as natural killer cells, macrophages, and neutrophils can all act as effector cells. The ADCC mechanism is an important way that antibodies prevent the spread of an infection.

Therapeutic antibodies can exert their affects via ADCC in the same way as naturally occurring antibodies.In cancer for instance, therapeutic monoclonal antibodies can bind to tumor antigens and signal immune cells to the site of the tumor. In the classical ADCC mechanism, natural killer cells serve as the effector cell. The natural killer cells express Fc receptors such as CD16 or FcyRIIIa on their cell surfaceswhich recognize and bind the Fc portion of tumor antigen-bound antibodies. The binding interaction triggers the natural killer cells to release cytokines like IFN-γ, causing the tumor cell to lyse.

Due to this important and broadly used mechanism of action in therapeutic antibody drug development, it is critical to assess the ability of these antibodies to induce ADCC at early stages of antibody development. BPS Bioscience offers ADCC cell lines expressing either the low (F158) affinity- or high (V158)-affinity variant. and the firefly luciferase gene under the control of NFAT response elements. An antibody is bound to the target antigen expressed on the target cell surface. When the Fc portion of the antibody binds to FcγRIIIa on the surface of effector cells, cross-linking of the effector and target cells occurs. This cross-linking leads to activation of the NFAT pathway and luciferase expression. 

In addition to these cell lines, BPS Bioscience also offers screening and profiling services. Trust us to provide you with high quality data with fast turnaround time. Our team of experts along with our broad services portfolio make it easy to:

  • Screen for inhibitors/targets using our ADCC assay
  • Select from IC50 determination and single point concentrations
  • Receive data within days of compound submission
  • Perform follow-up studies using the same soluble receptors manufactured in-house
  • Get questions answered or project guidance in a time-efficient manner

Contact BPS today to find out more about how we can assist you in your ADCC related research.

Not quite what you're looking for? We also offer custom assays for several other immunotherapy targets. Our Custom Assay Development Services allow for flexibility to meet your specific research needs